Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target. The ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead Sciences’ SuYvonne Bell explains how she’s rethinking fleet operations for sustainability, safety, and competitiveness in a post-COVID era.